TY - CHAP A1 - Radhamani Kannaiyan A2 - Rohit Surana A3 - Eun Myoung Shin A4 - Lalitha Ramachandran A5 - Gautam Sethi A6 - Alan Prem Kumar ED1 - Ajay Gupta Y1 - 2012-01-20 PY - 2012 T1 - Targeted Inhibition of Multiple Proinflammatory Signalling Pathways for the Prevention and Treatment of Multiple Myeloma N2 - Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. Much insight has been gained into the molecular pathways that lead to myeloma and indeed much more remains to be done. The understanding of these pathways is closely linked to their therapeutic implications and is stressed upon in the initial chapters. Recently, the introduction of newer agents such as bortezomib, lenalidomide, thalidomide, liposomal doxorubicin, etc. has led to a flurry of trials aimed at testing various combinations in order to improve survival. Higher response rates observed with these agents have led to their integration into induction therapies. The role of various new therapies vis a vis transplantation has also been examined. Recent advances in the management of plasmacytomas , renal dysfunction, dentistry as well as mobilization of stem cells in the context of myeloma have also found exclusive mention. Since brevity is the soul of wit our attempt has been to present before the reader a comprehensive yet brief text on this important subject. BT - Multiple Myeloma SP - Ch. 5 UR - https://doi.org/10.5772/30444 DO - 10.5772/30444 SN - PB - IntechOpen CY - Rijeka Y2 - 2021-09-26 ER -